



**PATIENT SELF-ASSESSMENT OF HOSPITAL PAIN AND
HEALTH RELATED QUALITY OF LIFE IN ADULTS WITH
SICKLE CELL DISEASE**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001274
Article Type:	Research
Date Submitted by the Author:	07-Apr-2012
Complete List of Authors:	Anie, Kofi; Central Middlesex Hospital, Haematology and Sickle Cell Centre Grocott, Hannah; Central Middlesex Hospital, Haematology and Sickle Cell Centre White, Lauren; Central Middlesex Hospital, Haematology and Sickle Cell Centre Dzingina, Mendwas; National Institute of Health and Clinical Excellence, Rogers, Gabriel; National Institute of Health and Clinical Excellence, Cho, Gavin; Central Middlesex Hospital, Haematology and Sickle Cell Centre
Primary Subject Heading:	Haematology (incl blood transfusion)
Secondary Subject Heading:	Patient-centred medicine
Keywords:	Sickle Cell Disease, Pain, Quality of Life, Health Utility

SCHOLARONE™
Manuscripts

only

PATIENT SELF-ASSESSMENT OF HOSPITAL PAIN AND HEALTH RELATED
QUALITY OF LIFE IN ADULTS WITH SICKLE CELL DISEASE

Kofi A Anie¹

Hannah Grocott¹

Lauren White¹

Mendwas Dzingina²

Gabriel Rogers²

Gavin Cho¹

¹Haematology and Sickle Cell Centre
Central Middlesex Hospital
London
NW10 7NS
UK

²National Institute of Health and Clinical Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BD
UK

Correspondence to:

Kofi Anie
Email: kofi.anie@nhs.net
Tel: +44 (0) 20 8453 2050
Fax: +44 (0) 20 8453 2051

1
2
3 SUMMARY
4
5
6

7 **Article Focus:**
8

9 Acute pain is a hallmark of sickle cell disease for which hospital admissions may be required.
10
11 This study explores the relationship between patient self-assessments of pain, mood, and
12
13 health related quality of life with health utility (measured on the EQ-5D) during and after
14
15 hospital admissions.
16
17

18 **Key Messages:**
19

20 Mood, general health, and quality of life steadily improve with reduction of pain during and
21
22 after an acute sickle cell pain episode.
23
24

25 A multidimensional approach to assessing sickle cell pain in hospital is useful. This helps to
26
27 identify co-morbidities such as mood changes that may affect length of stay with health care
28
29 coat implications.
30
31

32 **Strengths and Limitations:**
33

34 Health utility indices for an in-patient sickle cell pain population are reported for the first
35
36 time. Quality of life and emotional changes are also highlighted. Nonetheless, this is based on
37
38 information from one setting, and may be different from others.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 ABSTRACT
4

5 **Objectives:**
6

7 To characterize the relationship between adult patient self-reported sickle cell pain, mood and
8 quality of life during and after hospital admissions.
9

10
11
12
13 **Design:**

14 Longitudinal study across three time points.
15

16
17 **Setting:**

18 Secondary care, single specialist sickle cell centre
19

20
21 **Participants:**

22 510 adult patients with sickle cell disease admitted to hospital daycare or inpatient units.
23

24
25 **Outcome measures:**

26 Self-assessments of pain, mood, and health related quality of life with health utility
27 (measured on the EQ-5D) on admission, before discharge, and at one-week post discharge.
28

29
30
31 **Results:**

32 Mood, general health, and quality of life showed significant steady improvements with
33 reduction of pain in patients with sickle cell disease on admission to hospital, before
34 discharge, and at one-week follow-up ($p<0.01$). Health utility scores derived from the EQ-5D
35 showed a negative association with pain in regression analysis over the three time points.
36
37
38
39
40
41

42
43 **Conclusion:**

44 Examining health related quality of life and health utility in relation to pain during hospital
45 admissions is valuable in terms of targeting appropriate psychological interventions within
46 the context of a multidisciplinary approach to managing sickle cell pain. This has
47 implications for health care costs.
48
49
50
51

52
53
54
55 **KEY WORDS**
56

57 Sickle cell disease, Pain, Quality of life, Health utility
58
59
60

INTRODUCTION

Pain associated with vaso-occlusion in sickle cell disease (SCD) is a life-long persistent and significant problem, which has profound medical, psychological, and social implications for affected patients and their families. Recurrent acute pain episodes in SCD are variable for which frequent hospitalisations may be required^{1,2}. More than 90% of hospital admissions of patients with SCD in the UK have been shown to be for acute pain treatment³, and the management of acute painful episodes continues to pose a challenge for clinicians.

Sickle cell pain assessment is a crucial and difficult task. Accurate estimation of this pain is important in its control and management. Inadequate treatment for sickle cell pain continues to be an important problem, and a major issue is the restricted assessment methods utilised. Firstly, similar to other types of pain, there is no medical assessment or physiological measure of sickle cell pain that is objective. Pain assessment in patients with SCD is usually based on the opinion of clinical staff, and this may lead to discrepancies between their ratings of pain severity or the amount of pain relief required and that of patients⁴. Secondly, pain experiences are multidimensional, and quite importantly in sickle cell pain other dimensions including mood, general health, activity levels and sleep have to be considered⁵. In order to address these issues different strategies for the clinical management of sickle cell pain should be adopted to incorporate psychological assessments.

Patients with sickle cell pain who are admitted to Central Middlesex Hospital in London are treated with morphine (or alternative opioid) via a patient controlled analgesia (PCA) pump as standard. The multidisciplinary approach to the clinical management of sickle cell pain includes routine psychological assessments, which have been incorporated into the inpatient

1
2
3 protocols, and allow for appropriate interventions. These patients self-complete assessments
4 referred to as the 'Sickle Cell Patient Self Assessment of Own Health State' (Diagram 1),
5 which are administered on admission, before discharge, and at one week after discharge (by
6 telephone call from a psychologist). This assessment form is mainly a combination of Health
7 Related Quality of Life / Health Utility⁶ and pain status measures. The EQ-5D is a
8 standardised instrument for use as a measure of health outcome and health utility, which
9 provides a simple descriptive profile and a single index value for health status. Pain status
10 includes assessments of pain intensity and pain relief; there is also a mood score. The present
11 study is based on a retrospective audit review of standard psychological assessments in adults
12 with sickle cell pain admitted to Central Middlesex Hospital over a five-year period until the
13 end of 2010.
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28 29 OBJECTIVE

30
31
32
33 The main aim of the study was to define the relationship between adult patient self-reported
34 sickle cell pain, mood and health related quality of life (HRQoL) across three time-points
35 during and after hospital admissions.
36
37
38
39
40
41

42 METHODS

43
44
45
46 The 'Sickle Cell Patient Self Assessment of Own Health State' form comprises three sections
47 (Diagram 1). The first section taken from the EQ-5D measures HRQoL in five dimensions:
48 mobility; self-care; usual activities; pain/discomfort; anxiety/depression at three levels (1) no
49 problems, (2) some problems, (3) extreme problems. There is also a general rating of health
50 state on a scale of 0 (worst imaginable) to 100 (best imaginable). In the second section, there
51 are ratings of pain intensity 0 (no pain) to 10 (worst possible pain), pain relief 0 (no relief) to
52
53
54
55
56
57
58
59
60

1
2
3 10 (complete relief), mood 0 (worst mood) to 10 (best mood) and drowsiness 0 (not drowsy)
4
5 to 10 (asleep) on visual analogue scales (VAS). The final section requires patients to indicate
6
7 the location of their pain on a diagram of the body.
8
9

10
11
12 Data were extracted from consecutive cases of patients who were admitted over the five-year
13
14 period. These included patients admitted to the hospital Day-care centre, and Inpatient units
15
16 via the Accident and Emergency (A&E) department. There were three assessment time-
17
18 points: T1 – on admission to hospital; T2 – before discharge from hospital; T3 – 7 days post
19
20 discharge from hospital (telephone). Initial statistical analyses of demographic characteristics
21
22 and clinical characteristics included all patients.
23
24

25
26
27 The relationship between pain and HRQoL was examined over the three time-points since
28
29 this was of initial interest, and unique to this study. Health utility values were calculated from
30
31 the EQ-5D with a special calculator tool with data from various countries presented by
32
33 Szende *et al*⁷. UK health utility data is based on the time trade-off (TTO) valuation method
34
35 with weights derived from 3395 UK adults first reported by Kind *et al*⁸. The relationship
36
37 between pain score and EQ-5D-derived health utility was explored. Preliminary analysis
38
39 showed that there was no significant interaction between time-point and pain score in
40
41 predicting utility (i.e. although pain score decreased and utility increased over time, the
42
43 relationship between the two variables remained constant). Therefore, data from all time-
44
45 points were used in a single analysis. This approach meant that it was necessary to account
46
47 for within-person correlation, so a random-effects time-series regression model with *patient*
48
49 *ID* as a panel variable was used (xtreg command in Stata 8.0). Polynomial functions of pain
50
51 score were explored to improve model fit. Patient age and sex were not significant predictors
52
53 of utility (either as individual variables or in interaction with pain score), so these covariates
54
55
56
57
58
59
60

were not included in the model.

RESULTS

There were 510 admissions in total. Most of the patients had more than one hospital admission for acute sickle cell pain during the study period. Demographic characteristics of the patients are presented in Table 1.

Table 1: Demographic and Clinical Characteristics of Adult Patients with Sickle Cell Disease

Variable	Frequency
<i>Gender</i>	
Male	199 (39%)
Female	305 (60%)
Unreported	6 (1%)
<i>Location</i>	
Inpatient	463 (91%)
Day-care	47 (9%)
	Mean (SD)
<i>Age</i>	28.9 (10.2)

Day-care cases were excluded from t-test analyses owing to the difference in the length of stay from inpatient hospital admissions. Pain, mood, and general health status scores obtained from Inpatient cases are presented in Figure 1; in addition their health utility values obtained from the EQ-5D are presented in Figure 2.

Pain

There was a significant reduction of pain VAS scores from admission T1 (Mean 5.1, SD 2.5) to discharge T2 (Mean 3.0, SD 2.4), $t=9.29$, $df=482$, $p<0.001$ and from discharge T2 to one-week telephone follow up T3 (Mean 2.0, SD 2.2), $t=4.69$, $df=427$, $p<0.001$.

Mood

There was a significant improvement in mood VAS scores from admission T1 (Mean 5.0, SD 2.2) to discharge T2 (Mean 5.7, SD 2.3), $t=-3.23$, $df=479$, $p=0.001$, and from discharge T2 to one week follow up T3 (Mean 6.8, SD 2.2), $t=-4.90$, $df=425$, $p<0.001$.

General Health Status

Patients' reports of their general health on the VAS in addition showed significant improvements from admission T1 (Mean 47.7, SD 22.3) through discharge T2 (Mean 59.4, SD 21.7), $t=-5.70$, $df=459$, $p<0.001$, to one-week follow up T3 (Mean 71.0, SD 20.0), $t=-5.63$, $df=413$, $p<0.001$.

Health Related Quality of Life and Health Utility

Furthermore, health utility values derived from the EQ-5D showed that patients significantly got better between T1 (Mean 0.39, SD 0.40) and T2 (Mean 0.65, SD 0.29), $t=-7.95$, $df=475$, $p<0.001$, and from T2 to T3 (Mean 0.75, SD 0.26), $t=-3.94$, $df=421$, $p<0.001$.

Pain and Health Related Quality of Life / Health Utility

Figure 3 shows the relationship between pain and health utility for all patients across all three time-points. A simple linear model estimates the relationship as: $utility = 0.890 - 0.089pain$

1
2
3 ($R^2 = 0.437$). A slightly better fit to the data was obtained by introducing square and cube
4
5 functions to the model: $utility = 0.887 - 0.124pain + 0.014pain^2 - 0.001pain^3$ ($R^2 = 0.445$).
6
7

8 9 DISCUSSION

10
11
12
13
14 Acute pain episodes are the hallmark of SCD. Furthermore, adults with SCD have been
15
16 shown to have an impaired HRQoL as compared with the general population with pain and
17
18 psychological distress being contributors^{1,9}. Unsurprisingly in this study, there was a
19
20 significant reduction in pain scores from admission to discharge and at one-week follow-up.
21
22 Nonetheless, it was interesting to observe that patients were not completely pain free on
23
24 discharge and importantly at one-week follow-up. A large 6-month pain diary study of adult
25
26 patients with SCD showed that 29% had sickle cell pain everyday². This supports the notion
27
28 that acute pain episodes could develop into a type of chronic sickle cell pain.
29
30
31

32
33
34 Health utilities are cardinal values that reflect the preferences of an individual – or a society –
35
36 for different health outcomes. They are measured on an interval scale with zero (0) reflecting
37
38 states of health equivalent to death and one (1) reflecting perfect health. Some health states
39
40 are considered to be worse than death, and have a negative value. Combined with survival
41
42 estimates, health utilities can be used to generate quality-adjusted life years (QALYs) for use
43
44 in cost–utility analyses of medical treatment. The EQ-5D is one of the commonly used
45
46 HRQoL instruments for measuring health utilities. In this study, HRQoL and health utility
47
48 values improved over the three time-points. This demonstrates that, although HRQoL in
49
50 patients with SCD is considerably impaired during acute painful episodes in hospital with
51
52 improvements after discharge, daily function may not be restored for quite some time and
53
54 steady-state HRQoL is likely to remain impaired. The mean health utility index of 0.75 at
55
56
57
58
59
60

1
2
3 one-week follow-up is comparable to the mean health utility index of 0.72 obtained from SF-
4
5 36 scores in a similar UK community based adult SCD population¹. Studies from USA have
6
7 also reported similar HRQoL (SF-36) for people with SCD^{9,10}.
8
9

10
11 Although a correlation between pain and health utility is clearly identifiable in our dataset, it
12
13 is subject to a substantial degree of variability at the individual level. For example, it can be
14
15 seen in Figure 3 that one participant rated their pain level as 9 out of 10, suggesting very
16
17 intense discomfort, yet identified no health-state limitation on the EQ-5D questions (in the
18
19 process, answering 'I have no pain or discomfort' for the pain dimension of the instrument).
20
21 Nevertheless, on average, the expected negative correlation between pain score and health
22
23 utility is observed.
24
25
26
27

28
29 When estimating health utility from pain score, it may be appropriate to prefer the
30
31 polynomial model to the simple linear fit, on the mathematical basis that it provides a very
32
33 slightly superior reflection the data, and also on the theoretical basis that it is more sensitive
34
35 to high pain scores (producing lower estimated utility values). It is known that EQ-5D
36
37 measurements are subject to 'floor' effects, and it is credible that most people would prefer
38
39 death to the prospect of spending the rest of their lives with a pain score of 10 (i.e. in the most
40
41 excruciating pain imaginable); this is consistent with a utility value of less than zero for such
42
43 health states.
44
45
46
47
48

49 Pain is an important dimension in the HRQoL of patients with SCD. Patients with sickle cell
50
51 pain who are admitted to day-care, and through A&E seemed to have impaired HRQoL as a
52
53 result of pain, however this improved during the course of the admission, and at home over 7
54
55 days after discharge. In general, HRQoL is a crucial aspect of illness perception from the
56
57
58
59
60

1
2
3 patient's viewpoint, incorporating psychological, social, and disease related factors. In the
4
5 absence of a universal cure in SCD, the primary aim of treatment is to reduce the impact of
6
7 the disease (pain in this case), thus enhancing quality of life.
8
9

10
11 Mood changes in terms of anxiety and depression can be associated with sickle cell pain^{11,12}.
12
13 General health status is also of importance because it affects the psychological well-being of
14
15 the patient. Mood and general health improved through admission to one-week follow-up.
16
17 Apart from pain, these could contribute to length of stay in hospital. That is, co-morbidity
18
19 could lead to poorer health outcomes and reduced HRQoL in patients with SCD. People with
20
21 long-term medical conditions including pain, frequently use health services, and are likely to
22
23 have mental health problems such as depression and anxiety¹³. Providing psychological
24
25 interventions can lead to better outcomes and a reduction in health care costs¹⁴.
26
27
28
29
30
31
32
33

34 CONCLUSION

35
36
37
38 The study yielded results suggesting that a multidimensional approach to assessing patients
39
40 with SCD admitted to hospital is beneficial. This approach helps to identify problems for
41
42 which psychological support is required during and after the hospital admission, and is in
43
44 accordance with National Institute of Health and Clinical Excellence (NICE) guideline for the
45
46 management of patients with chronic illnesses¹⁵. Psychological interventions can be targeted
47
48 at inpatients to enhance the use of appropriate pain coping techniques, and strategies to
49
50 improve quality of life. Together with their treatment for sickle cell pain, this will help reduce
51
52 length of stay and related hospital costs.
53
54
55
56
57
58
59
60

1
2
3 AUTHORS CONTRIBUTION
4
5
6

7 Kofi Anie conceived, designed the study, and performed some statistical analyses. Hannah
8 Grocott and Lauren White were responsible for data collection and entry into the study
9 database. Gabriel Rogers and Mendwas Dzingina performed statistical analyses. Gavin Cho
10 was involved in the study oversight. Kofi Anie took the lead in the write up with review and
11 editing by Gabriel Rogers, Mendwas Dzingina, and Gavin Cho. All authors read and
12 approved the final manuscript.
13
14
15
16
17
18
19

20
21
22
23 COMPETING INTERESTS
24
25
26

27 Kofi Anie was a co-opted expert to the NICE Guideline Development Group for the Sickle
28 Cell Acute Painful Episode.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Anie KA, Steptoe A, Bevan DH. Sickle cell disease: pain, coping, and quality of life in a study of adults in the UK. *British Journal of Health Psychology*. 2002; 7: 331-344.
2. Smith WR, Penberthy LT, Bovbjerg VE et al. Daily Assessment of Pain in Adults with Sickle Cell Disease. *Annals of Internal Medicine*. 2008; 148:94-101.
3. Brozović M, Davies SC, Brownell AI. Acute admissions of patients with sickle cell disease who live in Britain. *British Medical Journal* 1987;294(6581):1206-8.
4. Shapiro BS, Benjamin LJ, Payne R et al. (1997). Sickle cell-related pain: perceptions of medical practitioners. *Journal of Pain and Symptom Management*. 1997; 14: 168-174.
5. Anie KA, Steptoe A. Pain, mood and opioid medication use in sickle cell disease. *The Hematology Journal*. 2003; 4: 71-73.
6. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. *Health Policy*. 1990; 16(3):199-208
7. Szende A, Oppe M, Devlin N.(Eds). EQ-5D value sets: Inventory, comparative review and user guide. EuroQol Group Monographs Volume 2. Springer, 2006.
8. Kind P, Hardman G, Macran S. UK Population norms for EQ-5D. York Centre for Health Economics, Discussion Paper, University of York 1999.
9. McClish DK, Penberthy LT, Bovbjerg VE et al. Health related quality of life in sickle cell patients: the PiSCES project. *Health Quality of Life Outcomes*. 2005; 3:50
10. Woods KF, Miller MD, Johnson MH et al. Functional status and well-being in adults with sickle cell disease. *Journal of Clinical Outcomes Management*. 1997; 4(5): 15-21.
11. Gil KM, Carson JW, Porter LS et al. Daily Mood and Stress Predict Pain, Health Care Use, and Work Activity in African American Adults With Sickle-Cell Disease. *Health Psychology*. 2004; 23: 267-274.
12. Porter LS, Gil KM, Carson JW et al. The Role of Stress and Mood in Sickle Cell Disease Pain: An Analysis of Daily Diary Data *Journal of Health Psychology*. 2005; 5: 53-63.
13. Chapman DP, Perry GS, Strine TW. The vital link between chronic disease and depressive disorders. *Preventing Chronic Disease*. 2005; 3(2): 1-3.
14. Chiles JA, Lambert MJ, Hatch AL (1999). 'The impact of psychological interventions on medical cost offset: A meta-analytic review'. *Clinical Psychology: Science and Practice*. 1999; 6(2): 204-220.

1
2
3 15. NICE Clinical Guideline 91. Depression in adults with a chronic physical health problem.
4 2009.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 **Figure 1: Pain, Mood, and General Health Status Scores of Adult Patients with Sickle**
4 **Cell Disease**
5 (General Health Scores are scaled down from 100 to 10)
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2: Health Utility Indices of Adult Patients with Sickle Cell Disease

For peer review only

Figure 3: Relationship between Sickle Cell Pain and Health Utility

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1
342x226mm (72 x 72 DPI)

Review only




Figure 2
301x170mm (72 x 72 DPI)

review only




Figure 3
203x175mm (72 x 72 DPI)



**PATIENT SELF-ASSESSMENT OF HOSPITAL PAIN, MOOD AND
HEALTH RELATED QUALITY OF LIFE IN ADULTS WITH
SICKLE CELL DISEASE**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001274.R1
Article Type:	Research
Date Submitted by the Author:	17-May-2012
Complete List of Authors:	Anie, Kofi; Central Middlesex Hospital, Haematology and Sickle Cell Centre Grocott, Hannah; Central Middlesex Hospital, Haematology and Sickle Cell Centre White, Lauren; Central Middlesex Hospital, Haematology and Sickle Cell Centre Dzingina, Mendwas; National Institute of Health and Clinical Excellence, Rogers, Gabriel; National Institute of Health and Clinical Excellence, Cho, Gavin; Central Middlesex Hospital, Haematology and Sickle Cell Centre
Primary Subject Heading:	Haematology (incl blood transfusion)
Secondary Subject Heading:	Patient-centred medicine
Keywords:	Sickle Cell Disease, Pain, Quality of Life, Mood, Health Utility

SCHOLARONE™
Manuscripts

Only

PATIENT SELF-ASSESSMENT OF HOSPITAL PAIN, MOOD, AND HEALTH
RELATED QUALITY OF LIFE IN ADULTS WITH SICKLE CELL DISEASE

Kofi A Anie¹

Hannah Grocott¹

Lauren White¹

Mendwas Dzingina²

Gabriel Rogers²

Gavin Cho¹

¹Haematology and Sickle Cell Centre
Central Middlesex Hospital
London
NW10 7NS
UK

²National Institute of Health and Clinical Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BD
UK

Correspondence to:

Kofi Anie
Email: kofi.anie@nhs.net
Tel: +44 (0) 20 8453 2050
Fax: +44 (0) 20 8453 2051

ABSTRACT

Acute pain is a hallmark of sickle cell disease for which frequent hospital admissions may be required, affecting the quality of life of patients. This study examined 510 adult inpatient self-assessments of pain, mood, and health related quality of life with health utility (measured on the EQ-5D) across three time points on admission, before discharge, and at one-week follow-up. Results showed that mood and health related quality of life steadily improve with reduction of pain during and after an acute sickle cell pain episode. Moreover, examining health utility in relation to pain during hospital admissions is valuable in terms of targeting appropriate psychological interventions within the context of a multidisciplinary approach to managing sickle cell pain. This has implications for health care costs.

INTRODUCTION

Pain associated with vaso-occlusion in sickle cell disease (SCD) is a life-long persistent and significant problem, which has profound medical, psychological, and social implications for affected patients and their families. Recurrent acute pain episodes in SCD are variable for which frequent hospitalisations may be required^{1,2}. More than 90% of hospital admissions of patients with SCD in the UK have been shown to be for acute pain treatment³, and the management of acute painful episodes continues to pose a challenge for haematologists.

Sickle cell pain assessment is a crucial and difficult task. Accurate estimation of this pain is important in its control and management. Inadequate treatment for sickle cell pain continues to be an important problem, and a major issue is the restricted assessment methods utilised. Firstly, similar to other types of pain, there is no medical assessment or physiological measure of sickle cell pain that is objective. Pain assessment and **treatment** in patients with SCD **have historically been** based on the opinion of clinical staff **within a particular medical setting**. This **may have led** to discrepancies between their ratings of pain severity or the amount of pain relief required and that of patients, **as highlighted in an earlier study**⁴. Secondly, pain experiences are multidimensional, and quite importantly in sickle cell pain other dimensions including mood, general health, activity levels and sleep have to be considered⁵. In order to address these issues different strategies for the clinical management of sickle cell pain should be adopted to incorporate psychological assessments.

Patients with sickle cell pain who are admitted to Central Middlesex Hospital in London are treated with morphine (or alternative opioid) via a patient controlled analgesia (PCA) pump as standard. The multidisciplinary approach to the clinical management of sickle cell pain

1
2
3 includes routine psychological assessments, which have been incorporated into the inpatient
4 protocols, and allow for appropriate interventions. These patients self-complete assessments
5 referred to as the 'Sickle Cell Patient Self Assessment of Own Health State' (Diagram 1),
6 which are administered on admission, before discharge, and at one week after discharge (by
7 telephone call from a psychologist). This assessment form is mainly a combination of Health
8 Related Quality of Life / Health Utility⁶ and pain status measures. The EQ-5D is a
9 standardised instrument for use as a measure of health outcome and health utility, which
10 provides a simple descriptive profile and a single index value for health status. Pain status
11 includes assessments of pain intensity and pain relief; there is also a mood score. The present
12 study is based on a retrospective audit review of standard psychological assessments in adults
13 with sickle cell pain admitted to Central Middlesex Hospital over a five-year period until the
14 end of 2010.

31 OBJECTIVE

32
33
34
35
36 The main aim of the study was to define the relationship between adult patient self-reported
37 sickle cell pain, mood and health related quality of life (HRQoL) across three time-points
38 during and after hospital admissions.

44 METHODS

45
46
47
48
49 This is a longitudinal hospital based study **examining data from a retrospective audit review.**
50 **Therefore, no research question or hypotheses was proposed, and formal ethics approval was**
51 **not required.** The 'Sickle Cell Patient Self Assessment of Own Health State' form comprises
52 three sections (Diagram 1). The first section taken from the **standardised** EQ-5D measures
53 HRQoL in five dimensions: mobility; self-care; usual activities; pain/discomfort;
54
55
56
57
58
59
60

1
2
3 anxiety/depression at three levels (1) no problems, (2) some problems, (3) extreme problems.
4
5 There is also a visual analogue scale to record self-rated health state on a scale of 0 (worst
6
7 imaginable) to 100 (best imaginable). The second section is adapted from the Memorial Pain
8
9 Assessment Card (Fisherman et al. 1987), a standardised measure of pain which provides
10
11 ratings of pain intensity 0 (no pain) to 10 (worst possible pain), pain relief 0 (no relief) to 10
12
13 (complete relief), mood 0 (worst mood) to 10 (best mood) and drowsiness 0 (not drowsy) to
14
15 10 (asleep) on visual analogue scales (VAS). The final section requires patients to indicate
16
17 the location of their pain on a diagram of the body.
18
19
20
21
22

23 Data were extracted from consecutive cases of patients who were admitted over the five-year
24
25 period. These included patients admitted to the hospital Day-care centre, and Inpatient units
26
27 via the Accident and Emergency (A&E) department. There were three assessment time-
28
29 points: T1 – on admission to hospital; T2 – before discharge from hospital; T3 – 7 days post
30
31 discharge from hospital (telephone). Initial statistical analyses of demographic characteristics
32
33 and clinical characteristics included all patients.
34
35
36
37
38

39 The relationship between pain and HRQoL was examined by combining all the data points
40
41 across three time-points since this was of initial interest, and unique to this study. Health
42
43 utility values were calculated from the EQ-5D with a special calculator tool with data from
44
45 various countries presented by Szende *et al*⁷. UK health utility data is based on the time
46
47 trade-off (TTO) valuation method with weights derived from 3395 UK adults first reported
48
49 by Kind *et al*⁸. The relationship between pain score and EQ-5D-derived health utility was
50
51 explored. Preliminary analysis showed that there was no significant interaction between time-
52
53 point and pain score in predicting utility (i.e. although pain score decreased and utility
54
55 increased over time, the relationship between the two variables remained constant).
56
57
58
59
60

1
2
3 Therefore, data from all **three** time-points were **combined** in a single analysis. This approach
4
5 meant that it was necessary to account for within-person correlation, so a random-effects
6
7 time-series regression model with *patient ID* as a panel variable was used (xtreg command in
8
9 Stata 8.0). Polynomial functions of pain score were explored to improve model fit. Patient
10
11 age and sex were not significant predictors of utility (either as individual variables or in
12
13 interaction with pain score), so these covariates were not included in the model.
14
15

16 17 18 RESULTS 19

20
21
22 There were 510 admissions in total. Most of the patients had more than one hospital
23
24 admission for acute sickle cell pain during the study period. Demographic characteristics of
25
26 the patients are presented in **Error! Reference source not found.** Day-care cases were excluded
27
28 from t-test analyses, and **Figures 1 and 2 (not from the utility analysis, Figure 3, as described**
29
30 **above). The average length of stay for inpatient hospital admissions with uncomplicated pain**
31
32 **episodes at Central Middlesex Hospital is about 3 days, whereas patients treated in day-care**
33
34 **are discharged within the same day, meaning the data are not comparable hence day-care**
35
36 **cases were removed from the analyses.** Pain, mood, and general health status scores obtained
37
38 from Inpatient cases are presented in Figure 1; in addition their health utility values obtained
39
40 from the EQ-5D are presented in Figure 2.
41
42
43
44

45 46 47 *Pain* 48

49
50 There was a significant reduction of pain VAS scores from admission T1 (Mean 5.1, SD 2.5)
51
52 to discharge T2 (Mean 3.0, SD 2.4), $t=9.29$, $df=482$, $p<0.001$ and from discharge T2 to one-
53
54 week telephone follow up T3 (Mean 2.0, SD 2.2), $t=4.69$, $df=427$, $p<0.001$.
55
56
57
58
59
60

Mood

There was a significant improvement in mood VAS scores from admission T1 (Mean 5.0, SD 2.2) to discharge T2 (Mean 5.7, SD 2.3), $t=-3.23$, $df=479$, $p=0.001$, and from discharge T2 to one week follow up T3 (Mean 6.8, SD 2.2), $t=-4.90$, $df=425$, $p<0.001$.

General Health Status

Patients' reports of their general health on the VAS in addition showed significant improvements from admission T1 (Mean 47.7, SD 22.3) through discharge T2 (Mean 59.4, SD 21.7), $t=-5.70$, $df=459$, $p<0.001$, to one-week follow up T3 (Mean 71.0, SD 20.0), $t=-5.63$, $df=413$, $p<0.001$.

Health Related Quality of Life and Health Utility

Furthermore, health utility values derived from the EQ-5D showed that patients significantly got better between T1 (Mean 0.39, SD 0.40) and T2 (Mean 0.65, SD 0.29), $t=-7.95$, $df=475$, $p<0.001$, and from T2 to T3 (Mean 0.75, SD 0.26), $t=-3.94$, $df=421$, $p<0.001$.

Pain and Health Related Quality of Life / Health Utility

Figure 3 shows the relationship between pain and health utility for all patients across all three time-points **combined**. A simple linear model estimates the relationship as: $utility = 0.890 - 0.089pain$ ($R^2 = 0.437$). A slightly better fit to the data was obtained by introducing square and cube functions to the model: $utility = 0.887 - 0.124pain + 0.014pain^2 - 0.001pain^3$ ($R^2 = 0.445$).

DISCUSSION

Acute pain episodes are the hallmark of SCD. Furthermore, adults with SCD have been shown to have an impaired HRQoL as compared with the general population with pain and psychological distress being contributors^{1,9}. Unsurprisingly in this study, there was a significant reduction in pain scores from admission to discharge and at one-week follow-up. Nonetheless, it was interesting to observe that patients were not completely pain free on discharge and importantly at one-week follow-up. A large 6-month pain diary study of adult patients with SCD showed that 29% had sickle cell pain everyday². This supports the notion that acute pain episodes could develop into a type of chronic sickle cell pain. **The ongoing prevalence of pain further highlights the need for a multidimensional approach to pain management which extends beyond hospitalisation, and incorporates psychological interventions with coping strategies which can relieve pain and psychological distress whilst enhancing quality of life post-discharge.**

Health utilities are cardinal values that reflect the preferences of an individual – or a society – for different health outcomes. They are measured on an interval scale with zero (0) reflecting states of health equivalent to death and one (1) reflecting perfect health. Some health states are considered to be worse than death, and have a negative value. Combined with survival estimates, health utilities can be used to generate quality-adjusted life years (QALYs) for use in cost–utility analyses of medical treatment. The EQ-5D is one of the commonly used HRQoL instruments for measuring health utilities. In this study, HRQoL and health utility values, improved over the three time-points. This demonstrates that, although HRQoL in patients with SCD is considerably impaired during acute painful episodes in hospital with improvements after discharge, daily function may not be restored for quite some time and

1
2
3 steady-state HRQoL is likely to remain impaired. The mean health utility index of 0.75 at
4
5 one-week follow-up is comparable to the mean health utility index of 0.72 obtained from SF-
6
7 36 scores in a comparable UK community based adult SCD population¹. Studies from USA
8
9 have also reported similar HRQoL (SF-36) for people with SCD ^{9,10}.

10
11
12
13
14 Although a correlation between pain and health utility is clearly identifiable in our dataset, it
15
16 is subject to a substantial degree of variability at the individual level. For example, it can be
17
18 seen in Figure 3 that one participant rated their pain level as 9 out of 10, suggesting very
19
20 intense discomfort, yet identified no health-state limitation on the EQ-5D questions (in the
21
22 process, answering 'I have no pain or discomfort' for the pain dimension of the instrument).
23
24 Nevertheless, on average, the expected negative correlation between pain score and health
25
26 utility is observed.
27
28
29
30
31

32 When estimating health utility from pain score, it may be appropriate to prefer the
33
34 polynomial model to the simple linear fit, on the mathematical basis that it provides a very
35
36 marginally superior reflection the data, and also on the theoretical basis that it is more
37
38 sensitive to high pain scores (producing lower estimated utility values). It is known that EQ-
39
40 5D measurements are subject to 'floor' effects, and it is credible that most people would
41
42 prefer death to the prospect of spending the rest of their lives with a pain score of 10 (i.e. in
43
44 the most excruciating pain imaginable); this is consistent with a utility value of less than zero
45
46 for such health states.
47
48
49
50
51

52 Pain is an important dimension in the HRQoL of patients with SCD. Patients with sickle cell
53
54 pain who are admitted to day-care, and through A&E seemed to have impaired HRQoL as a
55
56 result of pain, however this improved during the course of the admission, and at home over 7
57
58
59
60

1
2
3 days after discharge. In general, HRQoL is a crucial aspect of illness perception from the
4
5 patient's viewpoint, incorporating psychological, social, and disease related factors. In the
6
7 absence of a universal cure in SCD, the primary aim of treatment is to reduce the impact of
8
9 the disease (pain in this case), thus enhancing quality of life.
10

11
12
13
14 It should also be noted that HRQoL has a relationship with the psychological well-being and
15
16 experience in patients with pain, and this is influenced by their coping strategies. These
17
18 finding could have been influenced by these phenomena.
19

20
21
22
23 Mood changes in terms of anxiety and depression can be associated with sickle cell pain^{11,12}.
24
25 General health status is also of importance because it affects the psychological well-being of
26
27 the patient. Mood and general health improved through admission to one-week follow-up. **In
28
29 addition to pain, these factors could contribute to length of stay in hospital and would be an
30
31 interesting area for future research. People with long-term medical conditions including pain,
32
33 frequently use health services, and are likely to have co-morbid mental health problems such
34
35 as depression and anxiety¹³. The provision of psychological assessments and interventions,
36
37 in an acute hospital setting, could improve health outcomes by facilitating the use of effective
38
39 coping strategies¹ and managing co-morbid mood disorders. This could result in a reduced
40
41 length of stay in hospital, and a reduction in health care costs.**
42
43
44
45

46 47 CONCLUSION

48
49
50
51
52 The study yielded results suggesting that a multidimensional approach **to the assessment and
53
54 treatment of** patients with SCD admitted to hospital is beneficial. This approach helps to
55
56 identify problems for which psychological support is required during and after the hospital
57
58
59
60

1
2
3 admission, and is in accordance with National Institute of Health and Clinical Excellence
4 (NICE) guideline for the management of patients with chronic illnesses¹⁵. Psychological
5 interventions can be targeted at inpatients to enhance the use of appropriate pain coping
6 techniques, **alleviate any co-morbid mental health difficulties, and ultimately improve quality**
7 **of life**. Together with their usual treatment for sickle cell pain, this will help reduce length of
8 stay and related hospital costs.
9
10
11
12
13
14
15
16
17
18
19

20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

AUTHORS CONTRIBUTION

Kofi Anie conceived, designed the study, and performed some statistical analyses. Hannah Grocott and Lauren White were responsible for data collection and entry into the study database. Gabriel Rogers and Mendwas Dzingina performed statistical analyses. Gavin Cho was involved in the study oversight. Kofi Anie took the lead in the write up with review and editing by Gabriel Rogers, Mendwas Dzingina, and Gavin Cho. All authors read and approved the final manuscript.

COMPETING INTERESTS

Kofi Anie was a co-opted expert to the NICE Guideline Development Group for the Sickle Cell Acute Painful Episode.

The authors declare that there is: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

LICENCE AGREEMENT

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in BMJ editions and any other BMJ PGL products and sublicenses to exploit all subsidiary rights.

REFERENCES

1. Anie KA, Steptoe A, Bevan DH. Sickle cell disease: pain, coping, and quality of life in a study of adults in the UK. *British Journal of Health Psychology*. 2002; 7: 331-344.
2. Smith WR, Penberthy LT, Bovbjerg VE, McClish DK, Roberts JD, Dahman B, et al. Daily Assessment of Pain in Adults with Sickle Cell Disease. *Annals of Internal Medicine*. 2008; 148:94-101.
3. Brozović M, Davies SC, Brownell AI. Acute admissions of patients with sickle cell disease who live in Britain. *British Medical Journal* 1987;294(6581):1206-8.
4. Shapiro, B.S., Benjamin, L.J., Payne, R. and Heidrich, G. (1997). Sickle cell-related pain: perceptions of medical practitioners. *Journal of Pain and Symptom Management*.1997; 14: 168-174.
5. Anie KA and Steptoe A. Pain, mood and opioid medication use in sickle cell disease. *The Hematology Journal*. 2003; 4: 71-73.
6. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. *Health Policy*. 1990; 16(3):199-208
7. Szende A, Oppe M, Devlin N.(Eds). EQ-5D value sets: Inventory, comparative review and user guide. EuroQol Group Monographs Volume 2. Springer, 2006.
8. Kind P, Hardman G, Macran S. UK Population norms for EQ-5D. York Centre for Health Economics, Discussion Paper, University of York 1999.
9. McClish DK, Penberthy LT, Bovbjerg VE, Roberts JD, Aisiku IP, Levenson JL, Roseff SD, Smith WR. Health related quality of life in sickle cell patients: the PiSCES project. *Health Quality of Life Outcomes*. 2005; 3:50
10. Woods KF, Miller MD, Johnson MH, Tracy A, Kutlar A and Cassel CK (1997). Functional status and well-being in adults with sickle cell disease. *Journal of Clinical Outcomes Management*. 1997; 4(5): 15–21.
11. Gil KM, Carson JW, Porter LS, Scipio C, Bediako SM, Orringer E (2004). Daily Mood and Stress Predict Pain, Health Care Use, and Work Activity in African American Adults With Sickle-Cell Disease. *Health Psychology*. 2004; 23: 267-274.
12. Porter LS, Gil KM, Carson JW, Anthony KK, Ready. The Role of Stress and Mood in Sickle Cell Disease Pain: An Analysis of Daily Diary Data *Journal of Health Psychology*. 2005; 5: 53-63.
13. Chapman DP, Perry GS, Strine TW. 'The vital link between chronic disease and depressive disorders. *Preventing Chronic Disease*. 2005; 3(2): 1-3.

1
2
3 14. Chiles JA, Lambert MJ, Hatch AL (1999). 'The impact of psychological interventions on
4 medical cost offset: A meta-analytic review'. *Clinical Psychology: Science and Practice*.
5 1999; 6(2): 204–220.
6

7 15. NICE Clinical Guideline 91. Depression in adults with a chronic physical health problem.
8 2009.
9

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1: Demographic and Clinical Characteristics of Adult Patients with Sickle Cell Disease

Variable	Frequency
<i>Gender</i>	
Male	199 (39%)
Female	305 (60%)
Unreported	6 (1%)
<i>Location</i>	
Inpatient	463 (91%)
Day-care	47 (9%)
	Mean (SD)
<i>Age</i>	28.9 (10.2)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Pain, Mood, and General Health Status Scores of Adult Patients with Sickle Cell Disease

(General Health Scores are scaled down from 100 to 10)

For peer review only

Figure 2: Health Utility Indices of Adult Patients with Sickle Cell Disease


For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 3: Relationship between Sickle Cell Pain and Health Utility

For peer review only




257x169mm (96 x 96 DPI)

Review only


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



226x135mm (96 x 96 DPI)

review only



169x135mm (96 x 96 DPI)